Simple research view

MRK · Merck & Company, Inc.

$130.76 latest stored close

Detected setup Cup & Handle

Watch · Quality 22/100

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$MRK

Merck & Company, Inc.

Merck & Company, Inc. is a mega-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $323B.

Strong Buy · 96 Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 1 Data 1h 57m ago

$130.76 latest close

← Back Join to Watchlist $MRK Share card

Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Review six verdicts Inspect chart

Earnings-risk mode

Pre-earnings setup

Tuesday, August 4, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

MRK-0.24%

Sector proxy · XLV+0.51%

Broad market · SPY+0.02%

Same completed session window ending 2026-07-27. MRK was -0.75 points vs XLV. -0.26 points vs SPY.

CatalystUnavailable Stock reactionNegative Sector reactionSupportive Opening surgeUnavailable Event riskEarnings-driven

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.

Price $130.76 Jul 27 close

52W High $132.53 -1.3%

52W Low $76.66

Wks Since High 0w

Tight Wks 1

Base B1

SMA 50 $121.44

SMA 200 $110.71

Avg Vol 10,559,555

RS Rank 85

RS vs High -6.2%

RS Slope +1.3% ▲

Grp Rank #16/64

ADR% 2.5%

ATR(14) $3.32 (2.5%)

Rel Vol (today) 0.65×

Vol Pace N/A

U/D Vol 0.64

A/D Days 9A / 9D

A/D Rating C

VDU Bars 0/10 d

Power Trend 9d

Earnings 7d

$76.66

$132.53 97%

MRK Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for MRK.

Create Free Account

Setup Quality B+ 5/7 signals

Score trend

✓ Stage 2 · Advancing ✓ Power Trend 9d ✗ RS New High ✓ Trend 8/8 ✗ No Pattern ✓ CANSLIM 69.5 (B) ✓ Gatekeeper Base #1 (A)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$MRK · $130.76 · as of 2026-07-27 · multi-factor read

/ 100

Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$121.44 ↑

100-day$118.73 ↑

200-day$110.71 ↑

Bullish (50 > 200)

RSI (14)

Reading61.2 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateBullish

Histogram+0.320

Bullish — MACD above its signal line and above zero. Histogram expanding.

Bollinger Bands (20,2)

%B / Width85% · 8.8%

Squeeze — volatility compressing

Near the upper band — buyers in control. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol0.64 · Distribution

Rel volume0.65×

Distribution — volume is concentrated on down days; sellers dominate. Recent volume is easing versus its baseline.

Support & Resistance

R · $132.5352-week high

Price · $130.76now

S · $120.16swing level

S · $116.50swing level

S · $113.81swing level

Fibonacci · Uptrend swing

23.6%$126.72

38.2%$123.12

50.0%$120.22

61.8%$117.31

78.6%$113.17

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for MRK — plus the full 495-symbol scanner and Ask-the-Legends chat.

🔒 Start your 7-day free trial →

Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume distribution

Want this read in a legend's voice? 💬 Ask a Legend about MRK

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini B

Trend-template read: 10/12 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $130.76, MA150 $116.81, MA200 $110.71

1.2 150-day MA > 200-day MAMA150 $116.81 vs MA200 $110.71

Failing evidence

2. Quarterly EPS growth ≥ 25%-161.2% QoQ

2. Revenue growth ≥ 20% YoY+1.3% YoY

10/12 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 82

A: Annual earnings & revenue qualityRev +1.3% | ROE 17.9%

Failing evidence

C: Quarterly EPS acceleration ≥ 25%-161.2% QoQ

S: Volume ≥ 40% above average on breakoutVolume ratio 0.65x

4/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $130.76 vs MA200 $110.71

Failing evidence

Volume expansion above averageVolume ratio 0.65x

Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base

5/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$130.76

Relative strengthRS 82

Failing evidence

Volume vs average0.65x

Pivotal point cleared on expanding volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$130.76

Relative strengthRS 82

Failing evidence

Volume vs average0.65x

Box top broken on heavy volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$130.76

Relative strengthRS 82

Failing evidence

Volume vs average0.65x

Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending

4/6 checks

Method → Playbook → Ask →

Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

🕯 Latest candle: Shooting Star — Long upper shadow with a small body near the low — sellers rejected higher prices. A caution flag when price is extended above a pivot.

Unlock Follow-Through Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -3 C

Minervini · Grade Card

Fundamentals & leadership quality — Minervini SEPA criteria · 5/7 met

B 5/7 SEPA

Separate score from the 8-point Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ -161%

✗ Revenue growth ≥20% YoY +1%

✓ Gross margin ≥30% 78%

✓ ROE ≥17% 18%

✓ RS rating ≥80 (leadership) 82

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -1.3%

Method Playbook

📋 Trade it like O'Neil EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.

Pivot

Pro level

Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Cup & Handle

90.4 score

RS Score 82

Trend 8/8 ✓

CANSLIM 69.5* (B)

13.2% cup depth 6.4% handle

Why This Setup?

Cup & Handle

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

2/7 universals met

In a confirmed uptrend Stage 2 · Trend 8/8
Risk is defined No stop — undefined risk
Asymmetric reward No target set
Not chasing (in range) Pivot distance unknown
Volume confirms 0.7× average — light
Clear of earnings in 7 days — event risk
A relative-strength leader RS 85

Why these seven? → The Universal Edge

Minervini Trend Template

8/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $130.76 vs SMA150 $116.81 / SMA200 $110.71

SMA 150 above SMA 200 SMA150 $116.81 vs SMA200 $110.71

SMA 200 trending up Slope +4.37 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $121.44

Price above SMA 50 $130.76 vs SMA50 $121.44

30%+ above 52W low +70.6% from $76.66

Within 25% of 52W high -1.3% from $132.53

RS score above 70 RS 82

Fundamentals

52W Range

97%

Mkt Cap SEC

323.0B

EPS QoQ

-161%

Rev YoY

+1%

ROE

18%

Gross Margin

78%

D/E

0.94

EPS TTM

$7.28

P/E TTM

18.0x

Float

2.5B

Insider

No Buy

Company

Legend AI snapshot

Merck & Company, Inc.

MRK · NYSE · Health Technology · Pharmaceuticals: Major

$130.76latest close $323.0Bmarket cap 85RS rank 90setup score

O'Neil · Grade Card

CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market

B 69.5* CANSLIM * disqualified on C, M

C · Curr. EPS

A · Annual EPS

N · New Highs

100

S · Supply/Demand

L · Leader RS

I · Inst. Spons.

M · Market

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$106.03

W. Resist

$131.74

Weekly Structure

Trend Neutral

Tight Weeks 1

Confirmation Neutral

Scan History

20× streak

Jul 28

Cup & Handle ✓ Gate

Jul 28

Cup & Handle ✓ Gate

Jul 27

Cup & Handle ✓ Gate

90 0.0%

Jul 27

Cup & Handle ✓ Gate

90 0.0%

Jul 24

Wyckoff SOS ✓ Gate

76 -0.2%

Get the full picture on MRK

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial